BioSpace News Archive

Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec’s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.

Enzolytics, Inc. (OTC PINK:ENZC)(the today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment

Training in healthcare has transformed in response to challenges caused by the Covid-19 pandemic.

Orthopaedic surgeon Dr. Sarav Shah is the first in the state to offer patients an innovative and bone-conserving implant for total shoulder replacement surgery.

La Jolla, California--(Newsfile Corp. - January 19, 2021) - Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange).

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the efficacy and safety results from the pivotal Phase 3 study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be hosting an Investor Webcast Event on Tuesday, January 26, 2021 from 2:30-4:00 PM Eastern Standard Time (EST)

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that it will present new data from its SER-109 Phase 3 ECOSPOR III clinical study that confirm the intended pharmacological properties of this investigational microbiome therapeutic for recurrent C. difficile infection (CDI).

Foundation Medicine, Inc. announced the transition of Cindy Perettie, Chief Executive Officer, to Roche Diagnostics to lead the Molecular Lab Solutions business headquartered in Pleasanton, California effective April 6, 2021.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin; technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343.